Information from properly designed prospective randomized clinical trials provide the most powerful information about the strategies of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) for the management of coronary artery disease. A major disadvantage of these trials is that only a relatively small section of the overall spectrum of patients presenting -with coronary artery disease were enrolled for study. The corollary is that any results from these trials can only be applied to the same subset of patients.
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Different information is obtained from detailed analyses of patients from large databases such as the Duke University Database. Such a database includes patients with the full range of coronary artery disease. By identifying and correcting for demographic and coronary artery risk factors, comparisons can be made between different therapeutic strategies in all patients presenting with coronary artery disease. While both clinical trials and database analyses have advantages and disadvantages, the techniques are complimentary.
A disadvantage ofboth trial and database results is that the information becomes less relevant with the passage of time. Trials of PTCA versus CABG commenced in the late 1980s and the early 1990s. Since then, PTCA techniques have been supplemented by stenting, while coronary artery bypass surgery has evolved from the extensive use of vein grafts and a single internal thoracic artery graft, to the use of complete arterial grafting with perceived longterm benefits.
TRIALS OF PTCA VERSUS CORONARY ARTERY
The findings of a number of trials comparing an initial strategy of CABG with an initial strategy of angioplasty have been reported. The 3 largest trials are summarized below.
S u RCERY
THE RANDOMISED INTERVENTION TREATMENT OF ANGINA TRIAL (RITA) This trial examined 1101 patients with I-, 21, or 3-vessel coronary artery disease suitable for either CABG or PTCA.' In 97% of the patients randomly assigned to surgery, all target vessels were grafted. Revascularization of all target vessels was attempted in 87% of patients randomized to PTCA with an angiographic success rate of 87% (90% when occluded vessels were excluded). There were 34 deaths (18 CABG, 16 PTCA) and no evidence of treatment difference in the predefined combined primary event of death or definite myocardial infarction (43 CABG, 50 PTCA; relative risk 0.88, 95% confidence limits 0.59 to 1.29). After two and a half years, the results indicated that recovery after CABG was longer than recovery after PTCA. However, CABG leads to a lower risk of angina and fewer additional diagnostic and therapeutic interventions in the first 2 years. At two and a half years there was no significant difference in the risk of death or myocardial infarction.
EMORY ANGIOPLASTY VERSUS
This trial enrolled 393 patients with 2-and 3-vessel disease.* The study excluded patients with left main stenosis, old occlusions, or an ejection fraction of less than 25%. those in New York Heart Association functional class higher than 111, and patients with serious noncardiac illness. The results after 5 years showed no difference in terms of survival and incidence of myocardial infarction but more than 30% of the PTCA group required either further PTCA or CABG.
The BARI investigatorsg explored the hypothesis that in selected patients with multivessel disease, an initial strategy of PTCA does not result in a poorer 5-year outcome than CABG. Patients were randomized to an initial treatment strategy of CABG (914) or PTCA (915) and were followed for an average of 5.4 years. Analyses of outcome were performed on an intention to treat basis. PTCA did not significantly compromise 5-year survival in patients with multivessel disease when compared to CABG. Subsequent revascularization procedures were' required more often after PTCA than after surgery. For treated diabetes, 5-year survival was significantly better after surgery than after PTCA.
A meta-analysis of 3371 patients (CABG 1661, PTCA 1710) from 8 randomized trials comparing PTCA with surgery was undertaken by Pocock and colleagues? The mean duration of follow-up was 2.7 years. The total number of deaths following CABG was 73 and following PTCA it was 79 with a relative risk of 1.08 (95% confidence limits 0.79 to 1.50). Combined death and nonfatal myocardial infarction occurred in 154 CABG patients and 169 PTCA patients with a relative risk of 0.91 (95% confidence limits 0.89 to 1.37). The combined evidence showed no difference between these initial revascularization strategies.
DATABASE ANALYSIS
Database analysis provides large series of patients with the full range of manifestations of coronary artery disease. In the past, it was argued that comparing the results from different data sets was unsound. Different definitions of angina, unstable angina, urgent, emergency, and salvage procedures made such comparisons impossible.5 More recently, the standardization of definitions and an improved understanding of statistical methods involved have made such comparison$ more reasonable. Although a number of databases have been created around the world and more are in the making, only data from the Duke Medical Center Database are discussed here.
THE DUKE MEDICAL CENTER DATABASE
To determine the long-term survival benefits of bypass surgery and angioplasty versus medical therapy, 9263 patients at Duke University Medical Center between 1984 and 1990 with 1-, 2-, and 3-vessel coronary artery disease confirmed by coronary angiography were entered prospectively into this cardiovascular database: The annual follow-up was 97% complete at a mean interval of 5.3 years and a maximum interval.of 10 years. An anatomic coronary artery index was scaled so that zero was the risk of death in patients with no coronary disease and 100 was the risk of death in patients with at least 95% stenosis of the left main coronary artery: In their report, the exclusion of patients with less than 75% stenosis and those with left main stem disease resulted in 9 coronary anatomy groups, representing acontinuum of 1-, 2-, and 3vessel disease.
Outcomes were analyzed with the CASS Method A? All patients were initially assigned to the medical group and remained in this group unless CABG or PTCA were performed. Treatment groups were medicine (2449), PTCA (2924), or bypass surgery (3890). Differences between baseline characteristics were adjusted using the Cox proportional hazard model. The anatomic severity of coronary artery disease best defined the survival benefit from bypass surgery and angioplasty versus medical treatment. Hazard ratios were calculated from the adjusted survival for each anatomic subgroup to predict the relative benefits of the three possible pairs of treatment. One or both interventional treatments provided better long-term survival than medical treatment for all levels of coronary artery disease. All patients with single vessel disease except those with at least 95% proximal left anterior descending coronary stenosis benefited from angioplasty versus bypass. All patients with 3-vessel disease and those 2-vessel disease patients with 95% proximal left anterior descending coronary artery (LAD) stenosis benefited more from bypass surgery than from angioplasty. All other patients with 2-vessel disease and those with less than 95% proximal LAD stenosis had similar survival with either of the interventional treatments. The absolute survival benefit was greatest for patients with severe triple-vessel disease treated with bypass surgery. Comparisons of the 3 treatments in the 9 coronary anatomy groups were used to define principles for the selection of treatment. This study was the first to conclusively show the survival benefit of any interventional or medical therapy in patients with less severe forms of coronary artery disease. Survival benefits were greater than those seen in 3-vessel disease treated with bypass surgery.
The limitations of this sort of study are that treatment was not randomly assigned and these comparisons depend on the effectiveness of treatments and accurate statistical adjustment for differences in baseline characteristics. The validity of statistical adjustment across this wide range of variables could, therefore, be questioned. The difference in treatment groups following commencement and crossover may confound the results. Improvements in medical therapy, PTCA, stenting and arterial grafting continue to evolve.
In summary, the major randomized trials of angioplasty versus coronary artery bypass surgery indicate that in patients with single vessel disease, there is no disadvantage in the short-term from PTCA. Information from the Duke Database dggests that CABG is preferred in patients with 3-vessel disease and in those with 2-vessel disease and proximal LAD disease. It is better to perform PTCA in single-vessel disease and in 2-vessel disease without proximal LAD disease. The database also suggests that either form of intervention therapy is better than medical therapy.
While we have obtained valuable short-term information about the roles of PTCA and coronary artery bypass surgery over the last 10 years, a fundamental question remains as to the relative merits of PTCA and stenting procedures compared to a single well-performed coronary artery bypass operation.
